| Wanda Leatherman Estep, MD | |
|
3774 Bayley Dr Ste A, Lafayette, IN 47905-8654 | |
| (765) 807-8200 | |
| (765) 446-5155 |
| Full Name | Wanda Leatherman Estep |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 3774 Bayley Dr Ste A, Lafayette, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386632644 | NPI | - | NPPES |
| 000000379525 | Other | IN | ANTHEM PROVIDER NUMBER |
| 200463520 | Medicaid | IN | |
| 11508177 | Other | IN | CAQH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 01058311A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Franciscan Health Lafayette | Lafayette, IN | Hospital |
| Indiana University Health Frankfort Inc | Frankfort, IN | Hospital |
| Indiana University Health White Memorial Hospital | Monticello, IN | Hospital |
| Indiana University Health Arnett Hospital | Lafayette, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| American Health Network Of Indiana Llc | 9830093533 | 212 |
News Archive
Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.
Medical implants – from catheters that deliver long-term life support to joint replacements – may work better when their surfaces are on the rough side, new research suggests.
After seven years of a vigorous fight, Jim Hart worried he was running out of options. Diagnosed with prostate cancer at age 60, Hart had undergone virtually every treatment — surgery, radiation and hormones — to eradicate it. But a blood test showed that his level of prostate-specific antigen, which should have been undetectable, kept rising ominously. And doctors couldn't determine where the residual cancer was lurking.
Patients with stage 2 or stage 3 triple-negative breast cancer (TNBC) who had a pathologic complete response (pCR) after presurgery chemotherapy had increased event-free and overall survival compared with those who had more than minimal residual invasive disease at surgery following presurgery chemotherapy, according to results from the randomized phase II CALGB/Alliance 40603 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
A natural treatment for an antibiotic-resistant bacterial infection that causes blindness in infants can be effectively administered through a simple eye drop without causing irritation, Kingston University researchers have found.
› Verified 2 days ago
| Entity Name | American Health Network Of Indiana Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831236272 PECOS PAC ID: 9830093533 Enrollment ID: O20031124000691 |
News Archive
Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.
Medical implants – from catheters that deliver long-term life support to joint replacements – may work better when their surfaces are on the rough side, new research suggests.
After seven years of a vigorous fight, Jim Hart worried he was running out of options. Diagnosed with prostate cancer at age 60, Hart had undergone virtually every treatment — surgery, radiation and hormones — to eradicate it. But a blood test showed that his level of prostate-specific antigen, which should have been undetectable, kept rising ominously. And doctors couldn't determine where the residual cancer was lurking.
Patients with stage 2 or stage 3 triple-negative breast cancer (TNBC) who had a pathologic complete response (pCR) after presurgery chemotherapy had increased event-free and overall survival compared with those who had more than minimal residual invasive disease at surgery following presurgery chemotherapy, according to results from the randomized phase II CALGB/Alliance 40603 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
A natural treatment for an antibiotic-resistant bacterial infection that causes blindness in infants can be effectively administered through a simple eye drop without causing irritation, Kingston University researchers have found.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Wanda Leatherman Estep, MD 3743 Landmark Drive, Ste 200, Lafayette, IN 47905-6633 Ph: (765) 448-4511 | Wanda Leatherman Estep, MD 3774 Bayley Dr Ste A, Lafayette, IN 47905-8654 Ph: (765) 807-8200 |
News Archive
Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.
Medical implants – from catheters that deliver long-term life support to joint replacements – may work better when their surfaces are on the rough side, new research suggests.
After seven years of a vigorous fight, Jim Hart worried he was running out of options. Diagnosed with prostate cancer at age 60, Hart had undergone virtually every treatment — surgery, radiation and hormones — to eradicate it. But a blood test showed that his level of prostate-specific antigen, which should have been undetectable, kept rising ominously. And doctors couldn't determine where the residual cancer was lurking.
Patients with stage 2 or stage 3 triple-negative breast cancer (TNBC) who had a pathologic complete response (pCR) after presurgery chemotherapy had increased event-free and overall survival compared with those who had more than minimal residual invasive disease at surgery following presurgery chemotherapy, according to results from the randomized phase II CALGB/Alliance 40603 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
A natural treatment for an antibiotic-resistant bacterial infection that causes blindness in infants can be effectively administered through a simple eye drop without causing irritation, Kingston University researchers have found.
› Verified 2 days ago
Ian Reed, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2525 South St, Lafayette, IN 47904 Phone: 765-807-2320 Fax: 765-807-2330 | |
Martin Scheidt, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Walter Scholer Dr, Lafayette, IN 47909 Phone: 765-448-8000 Fax: 765-448-8257 | |
Alison Wright, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3750 Landmark Dr Ste A, Lafayette, IN 47905 Phone: 765-448-4511 Fax: 765-447-7312 | |
Jeffrey C Wang, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5177 Mccarty Ln, Lafayette, IN 47905 Phone: 765-448-8000 Fax: 765-448-7613 | |
Dr. Jhon M Nogales Pimienta, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 5165 Mccarty Ln, Lafayette, IN 47905 Phone: 765-838-7101 | |
Navid Ahsani, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3920 St Francis Way Ste 209, Lafayette, IN 47905 Phone: 765-775-2830 | |
John P Cusack, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3554 Promenade Pkwy, Suite F, Lafayette, IN 47909 Phone: 765-477-2200 Fax: 765-477-0277 |